Along with previous findings, in ICC, HHLA2 may not only work as an inhibitory checkpoint, but also potentially contribute to tumor progression through binding to TMIGD2, a recently identified ligand which is also involved in angiogenesis, or through other unknown mechanisms [18]. The gene discussed is HHLA2; the disease is intrahepatic cholangiocarcinoma.